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OBJECTIVES: Developing a parsimonious model to predict
breast and lung cancer incidence in Spain which enables the
assessment of cancer prevention and control policies suitability in
the medium run. METHODS: Incidence data were gathered from
the International Agency for Research on Cancer’s CI5 I-VIII
(Detailed) database, covering the period 1973 to 1996 for 5
Spanish regional registries. Yearly incidence data, disaggregated
by registry, age, and sex were pooled, resulting in n = 2,988
(lung) and n = 1,494 (breast). Registered incidence (count data)
was noticeably right-skewed, displaying a large proportion of
zeroes. Consequently, absolute incidence was parsimoniously
modeled by means of a zero-inﬂated negative binomial regres-
sion. Age (quadratic function), sex (only for the lung cancer
regression), a time trend, and the population covered by each
regional registry were included as explanatory variables.
“Certain zeros” were modeled as a decreasing function of age.
Finally, incidence predictions were projected to the Spanish
population. RESULTS: For both the lung and breast cancer
regressions, the coefﬁcients of all variables included were
strongly signiﬁcant (p < 0.001) and showed the expected signs. A
positive incidence time trend was found, reﬂecting that diagnosis
techniques have considerably evolved during the period of study.
A quadratic incidence-age relationship was evidenced, meaning
that there is a point from which incidence does not increase with
age. For the lung cancer regression, the male dummy variable
coefﬁcient was positive. The model proved strong out-of-sample
predictive power (e.g. 1996 breast cancer Spanish incidence,
estimated from 1973 to 1995 subsample data: observed: 31,424;
predicted: 31,964). Incidence curves by different sex and age
groups were also ﬁtted. CONCLUSIONS: This model constitutes
a simple adequate tool in predicting Spanish lung and breast
cancer incidence. Interestingly, the model enables health out-
comes researchers to evaluate the appropriateness of speciﬁc
cancer prevention or control policies in the medium run, by
including proxies of those as additional incidence predictors.
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OBJECTIVES: Pharmaceutical care aims at preventing and
reducing drug-related problems (DRP). The aim of this project
was to investigate DRP in breast cancer patients as well as to
compare two DRP-categorisation systems. METHODS: In
December 2007 a cross-sectional prospective survey was con-
ducted in a German gynaecological-oncology outpatient ward.
DRP were identiﬁed using patient interviews and chart reviews.
The identiﬁed DRP were categorised using the PI-Doc® and
PCNE system. Subpopulations were evaluated using variance
analyses, interrater agreement using Cohen’s Kappa (ê).
RESULTS: The analysed 36 patients developed on average 7.36
DRP per patient. Most frequent DRP were adverse drug reac-
tions (ADR) (70.94 %), interactions (11.70 %) and non-
compliance (4.53 %). Common DRP in the category ADR were
gastrointestinal (27.13 %), dermatological (24.47 %) and con-
stitutional symptoms (14.36 %). The difference in the number of
DRP between treatment-naive (median 2) and pre-treated
patients (7) was statistically signiﬁcant (p = 0.031). The differ-
ence in the number of DRP between adjuvant (median 7.5) vs.
palliative (7) and between different therapy regimens was not
statistically signiﬁcant. No correlation between patients’ age and
the number of DRP was found. The level of concordance for
categorisation of DRP was “good” using the PI-Doc® system
(ê = 0.795, rate of uncodable DRP 15.63 %) vs. “very good”
using the PCNE system (0.835, 12.50 %). For both categorisa-
tion systems additional codes were developed and tested. Intro-
ducing further codes led to a reduction of uncodable DRP (3.13
% vs. 4.17 %) but resulted in a lower rate of agreement (95.06
% to 82.81 % vs. 89.29 % to 78.26 %). CONCLUSIONS:
Variety and frequency of the detected DRP demonstrate the need
for pharmaceutical care in breast cancer patients especially for
prevention and management of ADR. The use of both categori-
sation systems was found to be limited in this setting.
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OBJECTIVES: To evaluate the impact of rituximab plus
cyclophosphamide and vincristine (R-CVP) compared to CVP
on patients’ quality of life, a Quality-adjusted Time Without
disease Symptoms or Treatment toxicity (Q-TWiST) analysis
was applied to data from a randomised trial (M39021) in 321
patients with advanced follicular lymphoma. METHODS:
Overall and progression-free survival were partitioned to esti-
mate three health state durations: relapse (REL), toxicity
(TOX)—all treatment-related-adverse events from start of study
treatment up to 28 days following last dose and/or progression;
and time without disease symptoms or toxicity (TWiST). Areas
under the curve, based on 53 month median follow-up data
truncated at 67 months due to disproportionate follow-up, were
retrospectively weighted using utilities coefﬁcients. 95% conﬁ-
dence intervals (CI) for differences in the health states between
treatments were calculated. RESULTS: R-CVP patients gained an
average of 15.17 months TWiST (95% CI, 8.65–16.06,
p < 0.0001), spent on average 11.30 months less time in relapse
(95% CI, 6.21–13.24 p < 0.0001) compared with CVP, without
any increase in the burden of toxicity (mean difference 0.24
months (95% CI, -0.34–0.48, p = 0.4409). With utility coefﬁ-
cients of 1.0 for all health states, the unadjusted mean difference
in survival between R-CVP and CVP was 4.11 months (95% CI,
0.50–6.05, p = 0.0143). Using the patient reported utility of
0.618 (Pettengell et al., 2008) for REL, an assumed utility of
0.618 for TOX, and an utility of 1.0 for TWiST, R-CVP patients
experienced an average of 8.30 months longer Q-TWiST com-
pared to CVP (95% CI, 5.82–10.87, p < 0.0001). All utility
combinations for TOX and REL (0.1–0.9) with a TWiST utility
of one resulted in a signiﬁcant (p < 0.01) gain in Q-TWiST for
R-CVP patients. CONCLUSIONS: Patients treated with R-CVP
for advanced follicular lymphoma experienced a signiﬁcant and
clinically relevant improvement in their quality-adjusted survival
time compared to CVP.
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